Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03876132
Other study ID # 29BRC19.0059_DEPREV
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 14, 2019
Est. completion date February 25, 2020

Study information

Verified date July 2020
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. But this law is currently extremely weakened, and in a press release of February 26, 2018, the French Society of Alcoology is alarmed by these developments.

Studies focusing on the impact of alcohol marketing focus largely on young adolescents, and the links between exposure to marketing and the initiation of alcohol. But beyond these links, there has been little work on the impact of alcohol marketing in vulnerable subjects with regular alcohol consumption. Consumption of alcohol is one of the first causes of hospitalization in France (Paille and Reynaud, 2015), the damage is often restricted to notions of dependency risks, but they can appear as soon as consumptions of 1 US / d (Guerin and Laplanche, 2013) and they mainly concern 45-64 year olds. To our knowledge, there are no studies on the impact of alcohol marketing conducted on regular alcohol users, depending on how they use alcohol (use, or use disorders). mild, moderate or severe) in patients enrolled in primary care and specialized addiction care.


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date February 25, 2020
Est. primary completion date February 25, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Patients aged 18 to 45 years with moderate or severe alcohol use disorders

- Followed in addiction at Brest CHRU

Exclusion Criteria:

- Major from 18 to 45 years

- Current consumption of alcohol (multi-monthly)

- Follow-up in primary care or addictology in Brest

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHRU de Brest Brest

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Brest Ecole des Hautes Etudes en Santé Publique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alcohol craving Evaluation of alcohol craving, evaluated by a visual analogue scale from 0 to 100. It is in the form of a straight line of 100 mm. In one ends is indicated: absence of pain, to the other: unbearable pain. The patient places a marks between these two ends depending on the intensity of his pain at a given time. In practice, it is a small plastic strip provided, on a face of a cursor mobilized by the patient, on the other with millimeter graduations read by the caregiver. 1 day
Secondary Level of anxiety Assessment of the level of anxiety felt before and after the interview evaluated by a visual analogue scale from 0 to 100 1 day
Secondary Perceived risks Evaluation of perceived risks related to stimuli by individual interviews following the presentation of advertising images. It is not a scale but in interview where feelings are raised. No score. 1 day
Secondary Sensitivity to stimuli Assessment of sensitivity to stimuli presented 1 day
Secondary Attractiveness of stimuli Evaluation of the attractiveness of stimuli by individual interviews following the presentation of advertising images. It is not a scale but in interview where feelings are raised. No score. 1 day
Secondary Alcohol consumed Evaluation of the categories of alcohol consumed 1 day
See also
  Status Clinical Trial Phase
Completed NCT03165942 - Neuroendocrine Response to Oral Alcohol Administration Phase 1
Recruiting NCT05343039 - Technology Enhanced Adolescent Mental Health (TEAM) N/A
Active, not recruiting NCT04070521 - EEG Monitoring in the Emergency Department
Completed NCT03169244 - Buproprion for Binge Drinking Phase 2
Recruiting NCT05246202 - Personalized Feedback Intervention for Latinx Drinkers With Anxiety N/A
Completed NCT05036499 - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain N/A
Recruiting NCT04368416 - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Not yet recruiting NCT04557631 - Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02448134 - A Community-Based Strategy for Preventing Underage Drinking N/A
Completed NCT02681406 - Smartphone Based Continuing Care for Alcohol N/A
Withdrawn NCT01796158 - Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Withdrawn NCT01511679 - Brain-imaging and Adolescent Neuroscience Consortium N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00907309 - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use Phase 1/Phase 2